This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Meaning-Centered Psychotherapy in Advanced Cancer

This study has been completed.
Information provided by:
National Center for Complementary and Integrative Health (NCCIH) Identifier:
First received: August 14, 2003
Last updated: August 16, 2006
Last verified: August 2006
We have developed an 8-week Meaning-Centered Group Psychotherapy designed to help patients with advanced cancer sustain or enhance a sense of meaning, peace and purpose despite the limitations of their cancer illness. This project's overall aim is to explore the feasibility and efficacy of this new and unique psychotherapy intervention for advanced cancer patients in enhancing psychological and spiritual well-being and quality of life by comparing it with a standard supportive group psychotherapy.

Condition Intervention Phase
Lymphoma, Non-Hodgkin Neoplasms Behavioral: Meaning-Centered Group Psychotherapy Behavioral: Standard Supportive Group Psychotherapy Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Educational/Counseling/Training
Official Title: Meaning-Centered Psychotherapy in Advanced Cancer

Resource links provided by NLM:

Further study details as provided by National Center for Complementary and Integrative Health (NCCIH):

Estimated Enrollment: 118
Study Start Date: May 2002
Estimated Study Completion Date: March 2006
Detailed Description:
As per Brief Summary

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 21 years of age or older;
  • English speaking;
  • Stage III or IV solid-tumor or Non-Hodgkin's Lymphoma;
  • Receiving ambulatory care at Memorial Sloan-Kettering Cancer Center in New York City;

Exclusion Criteria:

  • Significant psychiatric disturbance sufficient, in the investigator's judgment, to preclude participation in a group-format intervention;
  • Presence of cognitive impairment disorder, such as delirium or dementia that is sufficient, in the investigator's opinion, to preclude meaningful participation and/or informed consent;
  • Karnofsky Performance Rating Scale below 50 or physical limitations or illness severity sufficient to preclude participation in outpatient group psychotherapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00067288

United States, New York
Memorial Sloan-Kettering Institute for Cancer Research
New York, New York, United States, 10021
Sponsors and Collaborators
National Center for Complementary and Integrative Health (NCCIH)
Principal Investigator: William Breitbart, MD Memorial Sloan Kettering Cancer Center
OverallOfficial: Christopher Gibson, PhD Project Coordinator Memorial Sloan-Kettering Cancer Center
  More Information Identifier: NCT00067288     History of Changes
Other Study ID Numbers: R21AT001031-01 ( U.S. NIH Grant/Contract )
Study First Received: August 14, 2003
Last Updated: August 16, 2006

Keywords provided by National Center for Complementary and Integrative Health (NCCIH):
Stage 3 cancer;
Stage 4 cancer;
solid tumor cancer;
Non-Hodgkin's Lymphoma;
solid tumors;
end-stage cancer;
group psychotherapy;
emotional support;
support groups

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on September 21, 2017